Anti-factor Xa activity assays of direct-acting oral anticoagulants during clinical care: An observational study.
anti–factor Xa activity assay
apixaban
direct oral anticoagulant
retrospective electronic medical record
rivaroxaban
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
23
11
2020
revised:
09
04
2021
accepted:
14
04
2021
entrez:
20
5
2021
pubmed:
21
5
2021
medline:
21
5
2021
Statut:
epublish
Résumé
Direct-acting oral anticoagulants (DOACs) are increasingly used to prevent and treat thromboembolism. Although measurement of DOAC concentrations is not currently recommended as part of routine patient care, measurement of DOAC concentrations with anti-factor Xa activity assays have recently become clinically available. Our goal was to determine the clinical conditions under which DOAC concentration measurements are requested. Retrospective electronic medical record analysis of indications for DOAC concentration measurements by anti-factor Xa activity assay at a single academic medical center from July 2015 through April 2020. Ninety-one DOAC concentration measurements were made in 69 patients: 28 received apixaban and 41 received rivaroxaban. The most frequent indication for concentration measurement was drug exposure assessment (38/69; 55%) in patients with potentially altered pharmacokinetics (altered absorption or clearance), recurrent thromboembolic events, or possible medication nonadherence. Fourteen of 69 patients had repeated measurements during preoperative evaluation before emergent surgery; one-third of those with detectable levels upon presentation had repeated measurements until concentrations were undetectable. Levels were undetectable in 4 of 4 patients scheduled for elective surgery. Eleven of 69 patients had DOAC measurements in the setting of major bleeding; 5 of these 11 received a specific DOAC reversal agent. While most of the observed indications appear in clinical guidelines, altered absorption does not. Overall, clinicians are requesting DOAC concentration measurements to evaluate drug exposure in patients with conditions that might alter the absorption or clearance of the DOAC, to evaluate surgical bleeding risk, and in the setting of major bleeding.
Sections du résumé
BACKGROUND
BACKGROUND
Direct-acting oral anticoagulants (DOACs) are increasingly used to prevent and treat thromboembolism. Although measurement of DOAC concentrations is not currently recommended as part of routine patient care, measurement of DOAC concentrations with anti-factor Xa activity assays have recently become clinically available.
OBJECTIVES
OBJECTIVE
Our goal was to determine the clinical conditions under which DOAC concentration measurements are requested.
MATERIALS AND METHODS
METHODS
Retrospective electronic medical record analysis of indications for DOAC concentration measurements by anti-factor Xa activity assay at a single academic medical center from July 2015 through April 2020.
RESULTS AND CONCLUSIONS
CONCLUSIONS
Ninety-one DOAC concentration measurements were made in 69 patients: 28 received apixaban and 41 received rivaroxaban. The most frequent indication for concentration measurement was drug exposure assessment (38/69; 55%) in patients with potentially altered pharmacokinetics (altered absorption or clearance), recurrent thromboembolic events, or possible medication nonadherence. Fourteen of 69 patients had repeated measurements during preoperative evaluation before emergent surgery; one-third of those with detectable levels upon presentation had repeated measurements until concentrations were undetectable. Levels were undetectable in 4 of 4 patients scheduled for elective surgery. Eleven of 69 patients had DOAC measurements in the setting of major bleeding; 5 of these 11 received a specific DOAC reversal agent. While most of the observed indications appear in clinical guidelines, altered absorption does not. Overall, clinicians are requesting DOAC concentration measurements to evaluate drug exposure in patients with conditions that might alter the absorption or clearance of the DOAC, to evaluate surgical bleeding risk, and in the setting of major bleeding.
Identifiants
pubmed: 34013157
doi: 10.1002/rth2.12528
pii: S2475-0379(22)01396-6
pmc: PMC8114026
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12528Subventions
Organisme : NHLBI NIH HHS
ID : K24 HL141354
Pays : United States
Informations de copyright
© 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH).
Références
Int J Lab Hematol. 2019 May;41 Suppl 1:33-39
pubmed: 31069969
J Thromb Haemost. 2016 Mar;14(3):623-7
pubmed: 26911798
J Am Coll Cardiol. 2020 Aug 4;76(5):594-622
pubmed: 32680646
Am J Hematol. 2019 Jun;94(6):697-709
pubmed: 30916798
Nephron. 1976;16(1):31-41
pubmed: 1244564
J Thromb Haemost. 2018 Feb;16(2):209-219
pubmed: 29193737
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
J Am Heart Assoc. 2020 Jul 7;9(13):e017559
pubmed: 32538234
J Thromb Haemost. 2005 Apr;3(4):692-4
pubmed: 15842354
Blood Adv. 2018 Nov 27;2(22):3257-3291
pubmed: 30482765
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Thromb Haemost. 2018 Mar;118(3):437-450
pubmed: 29433148